TY - JOUR
T1 - Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention
AU - Zhao, Xueyan
AU - Li, Jianxin
AU - Tang, Xiaofang
AU - Xian, Ying
AU - Jiang, Lin
AU - Chen, Jue
AU - Gao, Lijian
AU - Gao, Zhan
AU - Qiao, Shubin
AU - Yang, Yuejin
AU - Gao, Runlin
AU - Xu, Bo
AU - Yuan, Jinqing
N1 - Funding Information:
This study was supported by grants from the National Key Research and Development Program of China (No. 2016YFC1301300 and No. 2016YFC1301301).
Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the National Key Research and Development Program of China (No. 2016YFC1301300 and No. 2016YFC1301301).
Publisher Copyright:
© The Author(s) 2019.
PY - 2019/6/18
Y1 - 2019/6/18
N2 - The Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) thrombotic risk score is a novel score for predicting the risk of coronary thrombotic events after percutaneous coronary intervention (PCI). We assessed the prognostic value of this score for mortality in patients with PCI. In this prospective, observational study, we enrolled 10 724 consecutive patients underwent PCI. The primary end point was all-cause death and the secondary end point was major adverse cardiovascular and cerebrovascular events (MACCE) as a composite of all-cause death, myocardial infarction, revascularization, stent thrombosis, or stroke. Among 9782 patients without in-hospital events, a total of 97 deaths and 1002 MACCE occurred during the 2-year follow-up. The mortality risk of patients in the high-risk group was 2.31 times higher than that in the low-risk group (hazard ratio, 2.31; P =.001). This risk score showed prognostic value in evaluating mortality (area under the receiver operating characteristic curve [AUROC], 0.607; 95% confidence interval [CI], 0.551-0.663) and MACCE (AUROC, 0.544; 95% CI, 0.526-0.563; both P <.001). The prognostic value of mortality was higher than that of MACCE (Z = 2.09, P =.04). The PARIS thrombotic risk score shows modest prognostic value for mortality and MACCE, and the prognostic value of mortality is better than that of MACCE.
AB - The Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) thrombotic risk score is a novel score for predicting the risk of coronary thrombotic events after percutaneous coronary intervention (PCI). We assessed the prognostic value of this score for mortality in patients with PCI. In this prospective, observational study, we enrolled 10 724 consecutive patients underwent PCI. The primary end point was all-cause death and the secondary end point was major adverse cardiovascular and cerebrovascular events (MACCE) as a composite of all-cause death, myocardial infarction, revascularization, stent thrombosis, or stroke. Among 9782 patients without in-hospital events, a total of 97 deaths and 1002 MACCE occurred during the 2-year follow-up. The mortality risk of patients in the high-risk group was 2.31 times higher than that in the low-risk group (hazard ratio, 2.31; P =.001). This risk score showed prognostic value in evaluating mortality (area under the receiver operating characteristic curve [AUROC], 0.607; 95% confidence interval [CI], 0.551-0.663) and MACCE (AUROC, 0.544; 95% CI, 0.526-0.563; both P <.001). The prognostic value of mortality was higher than that of MACCE (Z = 2.09, P =.04). The PARIS thrombotic risk score shows modest prognostic value for mortality and MACCE, and the prognostic value of mortality is better than that of MACCE.
KW - death
KW - major adverse cardiovascular and cerebrovascular events
KW - percutaneous coronary intervention
KW - prognosis
UR - http://www.scopus.com/inward/record.url?scp=85067846883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067846883&partnerID=8YFLogxK
U2 - 10.1177/1076029619853638
DO - 10.1177/1076029619853638
M3 - Article
C2 - 31215225
AN - SCOPUS:85067846883
SN - 1076-0296
VL - 25
JO - Clinical and Applied Thrombosis/Hemostasis
JF - Clinical and Applied Thrombosis/Hemostasis
ER -